-
based ImmunityBio Inc is
currently conducting phase 1
vaccine trials with
their hAd5
vaccine in the
United States and
South Africa.
ImmunityBio and
BioVac...
-
National Museum of
American History in
Washington DC. By
summer 2021,
ImmunityBio had
developed a T cell-inducing
universal COVID-19
vaccine booster shot...
- The
BioVac Institute, a state-backed
South African vaccine company, has a
contract with
American based ImmunityBio Inc. to
manufacture the
ImmunityBio vaccine...
-
vaccine developed by the
United States-based
pharmaceutical company ImmunityBio. The
BioVac Institute, a state-backed
South African vaccine company, plans...
-
Biovac Institute in
South Africa has a
contract with
ImmunityBio to
manufacture the
ImmunityBio COVID-19
vaccine and
distribute it
throughout Africa....
-
Archived from the
original on 30
April 2024.
Retrieved 30
April 2024. "
ImmunityBio Announces FDA
Approval of Anktiva, First-in-class IL-15
Receptor Agonist...
- (Ad26).
Recombinant adenovirus type-5 (Ad5) are
being used by Ad5-nCoV,
ImmunityBio and UQ-CSL V451. The Gam-COVID-Vac (aka Sputnik-V)
product is innovative...
-
China Bio-
Immunity,
based in Dalian, China, is
largest developer, producer,
manufacturer of vaccine-based
prophylactics and therapeutics. The
company has...
- (7): 1287–1294. doi:10.1111/jcmm.12810. PMC 4929308. PMID 27008316. "
ImmunityBio Announces NIH-Led
Research Affirming that PD-L1 T-haNK
Therapy Overcomes...
-
rights to the NK-92 cell line were ****igned to
ImmunityBio Inc. (formerly NantKwest, Inc.).
ImmunityBio's only
authorized NK-92
distributor is
Brink Biologics...
